Clinical performance with the Levitronix Centrimag short-term ventricular assist device

Area of Science:

• Cardiovascular Surgery
• Biomedical Engineering
• Mechanical Circulatory Support

Background:

• The Levitronix ventricular assist device (VAD) is a bearingless, seal-less centrifugal pump designed for extracorporeal circulatory support.
• Its magnetic levitation technology minimizes friction and wear, potentially reducing blood trauma and device failure.

Purpose of the Study:

• To report early clinical outcomes and device performance of the Levitronix Centrimag VAD.
• To evaluate the device's utility in patients with extremely poor prognoses.

Main Methods:

• A total of 18 patients received the Levitronix VAD between June 2003 and April 2005.
• Patients were categorized into two groups: post-cardiotomy cardiogenic shock (n=12) and bridge to decision (n=6).

Main Results:

• Mean support duration was 14.2 days, with a 30-day operative mortality of 50%.
• 33% of patients were discharged home, with no device failures reported.
• Complications included bleeding requiring re-operation (44%), cerebral thromboembolism (1), and pulmonary embolism (1).

Conclusions:

• The Levitronix Centrimag VAD is a viable option for critically ill patients, functioning reliably without mechanical complications.
• The device is technically straightforward to implant and manage.
• Survival to explant or definitive therapy was encouraging, suggesting its utility in high-risk populations.